HeartCore Enterprises, Inc. — Form 8-K Summary
Business Context and Reporting Period
HeartCore Enterprises, Inc. filed a Current Report on Form 8-K regarding a Consulting and Services Agreement entered into with SYLA Holdings Co. Ltd. on May 13, 2022. The filing was signed and dated May 25, 2022. HeartCore provides consulting support to Japanese companies pursuing U.S. initial public offerings and Nasdaq listings.
Transaction and Key Financial Terms
- Six-month consulting term, subject to renewal by mutual written agreement.
- Cash compensation of $500,000: $200,000 payable on the effective date, $150,000 on the three-month anniversary, and $150,000 on the six-month anniversary.
- Additional compensation for services beyond the term at $150 per hour.
- SYLA issued HeartCore a warrant, fully earned and vested on May 13, 2022, initially representing 2% of SYLA’s fully diluted share capital as of that date.
- The warrant has an exercise price of $0.01 per share and may be exercised after SYLA completes a qualifying U.S. IPO and through the tenth anniversary of the IPO date.
- The warrant is automatically adjusted at the IPO date to represent 2% of SYLA’s fully diluted listed shares, subject to the warrant’s adjustment provisions, and includes a 9.99% equity blocker.
The filing does not provide consolidated revenue, profit, cash flow, margin, debt, liquidity, warrant valuation, or other company-wide financial metrics for the period.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative financial statements or quantify changes versus a prior comparable period. It announces a new consulting engagement expected to generate $500,000 of initial fee revenue, plus potential value from the warrant.
Services, Outlook, and Risks
Services include support with selecting legal, underwriting, and audit firms; internal-control documentation; accounting-data conversion from Japanese standards to U.S. GAAP; document translation; preparation of S-1 or F-1 filings; Nasdaq listing support; and preparation of investor materials.
HeartCore will not perform accounting services or act as an investment adviser or broker-dealer. It also will not negotiate securities sales, participate in investor discussions, structure securities transactions, pre-screen investors, conduct due diligence, or advise on valuation or investment advisability.
Management stated that HeartCore cannot guarantee that SYLA will complete an IPO, satisfy Nasdaq listing standards, or obtain approval for a Nasdaq listing application. The warrant’s ultimate value and exercisability depend on SYLA completing a qualifying IPO and other warrant terms. The filing does not provide a specific revenue-recognition schedule or confirm the amount of cash actually received as of the filing date.
Important Facts for Investors to Verify
- Whether the $200,000 initial payment and subsequent installment payments were received when due.
- How and when the $500,000 contract consideration will be recognized as revenue under applicable accounting rules.
- The fair value and accounting treatment of the SYLA warrant.
- Whether SYLA ultimately completes a qualifying U.S. IPO and whether the warrant becomes exercisable.
- The final number and class of shares underlying the warrant after any IPO-date adjustment.
- Any subsequent amendments, renewals, termination, or disputes under the Consulting Agreement.